Background/aims To describe in patients diagnosed with intermediate uveitis (IU) the incidence rate (IR) of visual loss and newly diagnosed clinical complications during follow-up. Also, to analyse the influence of baseline complications on visual loss.
Methods Longitudinal retrospective cohort study which included 97 affected eyes of 67 consecutive patients diagnosed with IU according to the Standardization of Uveitis Nomenclature group, first seen in our clinic between 1986 and 2014, and until loss to follow-up, or 1 January 2015. Kaplan–Meier curves were set to account for temporary and permanent visual loss and development of clinical complications during follow-up. Cox's bivariate and multivariate regression models were constructed to examine the risk factors for visual loss.
Results IRs (in events per 100 eyes-year) for the development of cystic macular oedema (CMO), epiretinal membrane (ERM) and cataracts were 5.9 (3.70–9.4), 1.2 (0.50–2.6) and 6.6 (4.4–10.1), respectively. IRs per 100 eyes-year of temporary moderate and severe visual loss episodes were 43.8 (37.3–51.4) and 6.4 (4.5–9.0), respectively. IR of permanent moderate visual loss was 5.3 (3.3–8.3). After 2 years of follow-up, 21% of eyes had developed a permanent moderate visual loss. Presence at baseline of lower visual acuity was associated with higher IR of temporary visual loss episodes, and CMO was associated with higher IR of temporary moderate visual loss.
Conclusions IU seems to have a favourable long-term prognosis. Permanent visual loss occurs during the first year of the disease. Baseline characteristics could identify patients with a higher risk of poor visual prognosis.
Statistics from Altmetric.com
LR-R and BF-G share senior authorship.
Collaborators Uriarte-Vega, Cecilia del Rey-Ortega, Rafael Picón-Rodríguez.
Contributors LA, AP-G and DD-V contributed to the acquisition and analysis of the data. BF-G, JMBd-C, EP, JG-F and LR-R contributed to the design of the work and interpretation of the data. LA, DD-V, EP and LR-R contributed to the drafting of the manuscript. AP-G, BF-G, JMBd-C and JG-F revised the manuscript critically. All authors gave the final approval to the version submitted and agreed to be accountable for all aspects of the work, including accuracy or integrity of any part of the work.
Funding This work was supported by the Instituto de Salud Carlos III, Ministry of Health, Spain (Miguel Servet research contract: CP12/03129 to LRR).
Competing interests None declared.
Ethics approval Hospital Clínico San Carlos Ethics Committee.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.